SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period : a multicentre, prospective analysis
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Prolonged SARS-CoV-2 infections in people who are immunocompromised might predict or source the emergence of highly mutated variants. The types of immunosuppression placing patients at highest risk for prolonged infection have not been systematically investigated. We aimed to assess risk factors for prolonged SARS-CoV-2 infection and associated intrahost evolution.
METHODS: In this multicentre, prospective analysis, participants were enrolled at five US medical centres. Eligible patients were aged 18 years or older, were SARS-CoV-2-positive in the previous 14 days, and had a moderately or severely immunocompromising condition or treatment. Nasal specimens were tested by real-time RT-PCR every 2-4 weeks until negative in consecutive specimens. Positive specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with duration of infection.
FINDINGS: From April 11, 2022, to Oct 1, 2022, 156 patients began the enrolment process, of whom 150 were enrolled and included in the analyses. Participants had B-cell malignancy or anti-B-cell therapy (n=18), solid organ transplantation or haematopoietic stem-cell transplantation (HSCT; n=59), AIDS (n=5), non-B-cell malignancy (n=23), and autoimmune or autoinflammatory conditions (n=45). 38 (25%) participants were real-time RT-PCR-positive and 12 (8%) were culture-positive 21 days or longer after initial SARS-CoV-2 detection or illness onset. Compared with the group with autoimmune or autoinflammatory conditions, patients with B-cell dysfunction (adjusted hazard ratio 0·32 [95% CI 0·15-0·64]), solid organ transplantation or HSCT (0·60 [0·38-0·94]), and AIDS (0·28 [0·08-1·00]) had longer duration of infection, defined as time to last positive real-time RT-PCR test. There was no significant difference in the non-B-cell malignancy group (0·58 [0·31-1·09]). Consensus de novo spike mutations were identified in five individuals who were real-time RT-PCR-positive longer than 56 days; 14 (61%) of 23 were in the receptor-binding domain. Mutations shared by multiple individuals were rare (<5%) in global circulation.
INTERPRETATION: In this cohort, prolonged replication-competent omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting longer than 56 days accumulated spike mutations, which were distinct from those seen globally. Populations at high risk should be targeted for repeated testing and treatment and monitored for the emergence of antiviral resistance.
FUNDING: US Centers for Disease Control and Prevention.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
The Lancet. Microbe - 5(2024), 3 vom: 11. März, Seite e235-e246 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raglow, Zoe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 27.03.2024 published: Print-Electronic UpdateOf: medRxiv. 2023 Aug 24;:. - PMID 37662226 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2666-5247(23)00336-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367764784 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367764784 | ||
| 003 | DE-627 | ||
| 005 | 20240327235717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2666-5247(23)00336-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM367764784 | ||
| 035 | |a (NLM)38286131 | ||
| 035 | |a (PII)S2666-5247(23)00336-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raglow, Zoe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period |b a multicentre, prospective analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2023 Aug 24;:. - PMID 37662226 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Prolonged SARS-CoV-2 infections in people who are immunocompromised might predict or source the emergence of highly mutated variants. The types of immunosuppression placing patients at highest risk for prolonged infection have not been systematically investigated. We aimed to assess risk factors for prolonged SARS-CoV-2 infection and associated intrahost evolution | ||
| 520 | |a METHODS: In this multicentre, prospective analysis, participants were enrolled at five US medical centres. Eligible patients were aged 18 years or older, were SARS-CoV-2-positive in the previous 14 days, and had a moderately or severely immunocompromising condition or treatment. Nasal specimens were tested by real-time RT-PCR every 2-4 weeks until negative in consecutive specimens. Positive specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with duration of infection | ||
| 520 | |a FINDINGS: From April 11, 2022, to Oct 1, 2022, 156 patients began the enrolment process, of whom 150 were enrolled and included in the analyses. Participants had B-cell malignancy or anti-B-cell therapy (n=18), solid organ transplantation or haematopoietic stem-cell transplantation (HSCT; n=59), AIDS (n=5), non-B-cell malignancy (n=23), and autoimmune or autoinflammatory conditions (n=45). 38 (25%) participants were real-time RT-PCR-positive and 12 (8%) were culture-positive 21 days or longer after initial SARS-CoV-2 detection or illness onset. Compared with the group with autoimmune or autoinflammatory conditions, patients with B-cell dysfunction (adjusted hazard ratio 0·32 [95% CI 0·15-0·64]), solid organ transplantation or HSCT (0·60 [0·38-0·94]), and AIDS (0·28 [0·08-1·00]) had longer duration of infection, defined as time to last positive real-time RT-PCR test. There was no significant difference in the non-B-cell malignancy group (0·58 [0·31-1·09]). Consensus de novo spike mutations were identified in five individuals who were real-time RT-PCR-positive longer than 56 days; 14 (61%) of 23 were in the receptor-binding domain. Mutations shared by multiple individuals were rare (<5%) in global circulation | ||
| 520 | |a INTERPRETATION: In this cohort, prolonged replication-competent omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting longer than 56 days accumulated spike mutations, which were distinct from those seen globally. Populations at high risk should be targeted for repeated testing and treatment and monitored for the emergence of antiviral resistance | ||
| 520 | |a FUNDING: US Centers for Disease Control and Prevention | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Surie, Diya |e verfasserin |4 aut | |
| 700 | 1 | |a Chappell, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yuwei |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Emily T |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Jennie H |e verfasserin |4 aut | |
| 700 | 1 | |a Frosch, Anne E |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Amira |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Bendall, Emily E |e verfasserin |4 aut | |
| 700 | 1 | |a Bahr, Auden |e verfasserin |4 aut | |
| 700 | 1 | |a Halasa, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Talbot, H Keipp |e verfasserin |4 aut | |
| 700 | 1 | |a Grijalva, Carlos G |e verfasserin |4 aut | |
| 700 | 1 | |a Baughman, Adrienne |e verfasserin |4 aut | |
| 700 | 1 | |a Womack, Kelsey N |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Cassandra |e verfasserin |4 aut | |
| 700 | 1 | |a Swan, Sydney A |e verfasserin |4 aut | |
| 700 | 1 | |a Koumans, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a McMorrow, Meredith L |e verfasserin |4 aut | |
| 700 | 1 | |a Harcourt, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Atherton, Lydia J |e verfasserin |4 aut | |
| 700 | 1 | |a Burroughs, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Thornburg, Natalie J |e verfasserin |4 aut | |
| 700 | 1 | |a Self, Wesley H |e verfasserin |4 aut | |
| 700 | 1 | |a Lauring, Adam S |e verfasserin |4 aut | |
| 700 | 0 | |a Investigating Respiratory Viruses in the Acutely Ill (IVY) Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Microbe |d 2020 |g 5(2024), 3 vom: 11. März, Seite e235-e246 |w (DE-627)NLM312200277 |x 2666-5247 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:3 |g day:11 |g month:03 |g pages:e235-e246 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2666-5247(23)00336-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 3 |b 11 |c 03 |h e235-e246 | ||